The Genomic Landscape of MYC, MYCL, and MYCN Amplified Solid Tumors [0.03%]
MYC、MYCL和MYCN扩增的实体肿瘤的基因组景观
Matteo Repetto,Allison L Richards,Monica F Chen et al.
Matteo Repetto et al.
Purpose: MYC, MYCN and MYCL amplifications are recurrent oncogenic events across solid tumors. Currently, no standardized selection biomarker is available to identify patients with MYC-dependent tumors. ...
Investigational clinical trial agents versus conventional second salvage therapies in patients with relapsed/refractory acute myeloid leukemia [0.03%]
复发/难治性急性髓系白血病患者中临床试验药物与二线挽救治疗的比较研究
Daniel Nguyen,Hagop M Kantarjian,Aram Bidikian et al.
Daniel Nguyen et al.
Purpose: Outcomes in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) remain discouraging despite rapid expansion of treatment paradigms over the past decade. Clinicians must often decide between conve...
The first-in-human ENCIT01 trial comparing second- versus third-generation L1CAM-specific CAR T cells in patients with primary refractory or relapsed neuroblastoma [0.03%]
针对难治或复发性神经母细胞瘤患者比较第二代和第三代L1CAM特异性CAR-T细胞的首个人体I期ENCIT01试验
Navin Pinto,Annette Künkele,Catherine M Albert et al.
Navin Pinto et al.
Purpose: Outcomes for children with relapsed and refractory neuroblastoma are dismal. ENCIT-01 (NCT02311621) was a first-in-human clinical trial for patients with relapsed and refractory neuroblastoma using chimeric antig...
A multicentre phase 2 study of trifluridine/tipiracil in recurrent/metastatic platinum resistant nasopharyngeal carcinomas [0.03%]
特氟瑞/ tipiracil治疗复发/转移性铂类耐药鼻咽癌的多中心二期临床研究
Jia Li Low,Wan Qin Chong,Edwin Pun Hui et al.
Jia Li Low et al.
Purpose: Therapeutic options beyond platinum, gemcitabine and immunotherapy in r/m NPC remain limited. Median overall survival for R/M disease is 20 months. This study evaluated the efficacy and safety of FTD/TPI in plati...
Pulsed Electric Field Ablation Reprograms Tumor Immunity and Stimulates Germinal Center Formation in Tertiary Lymphoid Structures in Patients with Non-Small Cell Lung Cancer [0.03%]
脉冲电场消融可重新编程非小细胞肺癌患者的肿瘤免疫并刺激 tertiary lymphoid structure 中生发中心的形成
Marcelo Jimenez,Beryl A Hatton,Alicia Moreno-Gonzalez et al.
Marcelo Jimenez et al.
Purpose: This treat-and-resect clinical study evaluated a specialized form of pulsed electric field (PEF) ablation's potential to modulate antitumor immunity in early-stage non-small cell lung cancer (NSCLC). Tertiary lym...
Patrick C Lee,Michael T Schweizer,Rosa Nadal
Patrick C Lee
P-PSMA-101 is a first-in-class, stem cell memory T cell-enriched, PSMA-targeting CAR-T therapy. This cellular therapy showed notable clinical activity in two patients; however, PSA50 responses were generally modest. While severe immune effe...
Eric Deutsch,Antonin Levy,Laurence Zitvogel
Eric Deutsch
Low-dose intestinal irradiation challenges the long-standing view of the gut as a radiation-sensitive organ to avoid. Clinical and mechanistic data suggest that targeted exposure of the small intestine within a 1 to 3 Gy window can remodel ...
Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-Cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study [0.03%]
CAR-T细胞治疗或其他全身抗肿瘤治疗后多发性骨髓瘤患者第二原发恶性肿瘤的发病风险：一项真实世界比较研究
Attaya Suvannasankha,Mengying Li,Omonefe Omofuma et al.
Attaya Suvannasankha et al.
Purpose: This study aims to compare the risk of second primary malignancy (SPM) between patients with multiple myeloma (MM) who received CAR T therapy versus other systemic anticancer therapies (SACTs). ...
The biology of hypomorphic TP53 variants and implications for clinical management [0.03%]
Hypomorphic TP53变异的生物学特性及其对临床治疗的启示
Renyta Moses,Jacquelyn Powers,Alison S Levine et al.
Renyta Moses et al.
In individuals with classic Li Fraumeni Syndrome (LFS) due to a loss of function pathogenic germline variant in TP53, loss of p53 tumor suppressive function leads to a high risk of childhood cancers such as sarcomas, adrenal cortical carcin...
Molecular and clinical characteristics of patients with non-small cell lung cancer (NSCLC) harboring KRAS Q61 mutations to assess therapeutic responses [0.03%]
用于评估治疗反应的非小细胞肺癌（NSCLC）患者中携带KRAS Q61突变的分子和临床特征研究
Lea Ruge,Felix John,Malte Verheyen et al.
Lea Ruge et al.
Introduction: KRAS Q61 mutations represent a heterogeneous molecular subgroup and account for 1-7% of allKRAS mutations in non-small cell lung cancer (NSCLC). The prognostic value of this cohort and its response to differ...